Page Title
Clinical Trial Finder
Blaze a trail to better treatments and a cure for cystic fibrosis.
As a clinical trial volunteer, you are paving the way for new treatments. Search or filter for trials that may be right for you, or learn more about what it means to be a trailblazer.
Showing 1-3 of 3 studies
As a clinical trial volunteer, you are paving the way for new treatments. Search for trials that may be right for you using the filter on the left, or learn more about what it means to be a trailblazer.
Showing 1-3 of 3 studies
-
Anti-InfectiveEnrolling
Study to evaluate inhaled AR-501 in healthy adults and adults with cystic fibrosis and Pseudomonas aeruginosa , protocol number Aridis AR-501-001 MAD cohortsThis study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
45% or greater
-
Number of Visits:
11
-
Length of Participation:
6 weeks
-
-
Anti-InfectiveEnrolling
ABATE: Study to evaluate IV gallium in adults with cystic fibrosis who have nontuberculous mycobacteria (NTM) , protocol number ABATE-IP-18This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of IV gallium, a drug intended to treat infections in the lung.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25% or greater
-
Number of Visits:
8
-
Length of Participation:
20 weeks
-
-
Anti-InfectiveCompleted with Results
IGNITE: Safety and effectiveness of gallium nitrate in adults with cystic fibrosis , protocol number GALLIUM-IP-13This study evaluated the safety and effectiveness of intravenous (IV) gallium nitrate in adults with CF who are chronically infected with Pseudomonas aeruginosa.
-
Age:
18 Years and Older
-
Mutation(s):
No Mutation Requirement
-
FEV1% Predicted:
25% or greater
-
Number of Visits:
5
-
Length of Participation:
63 days
-
Showing 1-3 of 3 studies
- 1
Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.
Related Topics
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More